Oesophagogastric junction adenocarcinoma: which therapeutic approach?
Gastric and oesophageal cancers are among the leading causes of cancer-related death worldwide. By contrast with the decreasing prevalence of gastric cancer, incidence and prevalence of oesophagogastric junction adenocarcinoma (OGJA) are rising rapidly in developed countries. We provide an update about treatment strategies for resectable OGJA. Here we review findings from the latest randomised trials and meta-analyses, and propose guidelines regarding endoscopic, surgical, and perioperative treatments. Through a team approach, members from all diagnostic and therapeutic disciplines, such as gastroenterologists, surgeons, oncologists, radiologists, and radiotherapists, can effectively administer a range of treatment modalities.
Department of Digestive and Oncological Surgery, University Hospital C Huriez, Lille, France. c-mariette@chru-lille.fr
Christophe
C
Mariette
Guillaume
G
Piessen
Nicolas
N
Briez
Caroline
C
Gronnier
Jean Pierre
JP
Triboulet
D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D004943:Esophagogastric Junction / Q000473:pathology; D006801:Humans; D013274:Stomach Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
D000970:Antineoplastic Agents